Rallybio Stockholders Approve Avenzo Merger, Name Change and Reverse Split
Rallybio (RLYB) stockholders approved a merger with Avenzo Therapeutics, a name change, and a reverse stock split. They also elected four directors, ratified Deloitte & Touche as auditor, and approved equity plans. The company will file final results in a Form 8-K. Rallybio focuses on rare disease treatments, with RLYB212 as its lead program.
How this was made

The 30-second read
Why it matters
The approval clears a key hurdle for the transaction, likely unlocking value for shareholders and setting the stage for post‑merger integration.
Market read
The merger approval is a material corporate action for RLYB, potentially driving short‑term price appreciation.
What to watch
Potential regulatory review of the merger and dilution from the reverse split.
Background
Rallybio announced a shareholder meeting where the Avenzo Therapeutics merger, name change, and reverse split were approved, along with new equity incentive and employee stock purchase plans.
Ticker impact
Stockholders approved the Avenzo merger, name change and reverse split for Rallybio (RLYB).
upward pressure as the market prices in the completed merger and reverse split.
The article reports the first public confirmation of the merger and related corporate actions, a material catalyst for a micro‑cap biotech.
Market effects
Consolidation in rare‑disease biotech may prompt peer re‑valuation.
Limited to U.S. biotech investors.
Minor, confined to niche biotech segment.
Counterpoint
If the merger integration risks outweigh synergies, the stock could face downside.
Key entities
- companyRallybio Corporation
Clinical‑stage biotech focused on rare diseases, ticker RLYB.
- companyAvenzo Therapeutics Inc.
Target of the merger with Rallybio.
